Re-analysis of RESONATE-2 trial of ibrutinib vs chlorambucil in CLL
What influence do circulating myeloma plasma cells have on the treatment of multiple myeloma?
Comparing ibrutinib efficacy and toxicity levels by age for patients with CLL/SLL
FCR or FR – which regimen is better for treating CLL?
How to manage relapsed/refractory MCL - new agents and unmet needs